A diarylethene compound represented by formula (I) ##STR00001##
wherein, Sg is a monovalent sugar residue formed by removing one hydroxyl group from a sugar compound or a monovalent protected sugar residue formed by removing one hydroxyl group from a sugar compound in which one or more other hydroxyl groups are protected, and wherein the sugar is selected from the group consisting of a six-membered ring sugar, a five-membered ring sugar, cyclitol, and oligosaccharides containing a six-membered ring sugar, a five-membered ring sugar, or cyclitol; U is —(CH.sub.2).sub.n—, —CH.sub.2—U′—, or —C(═O)— wherein n is an integer of 1 to 5, U′ is a C2-C10 branched alkylene group binding to Ar); and Ar is a group represented by formula (A1) or (A2); ##STR00002## wherein, X is S, SO.sub.2, NR.sub.3 in which R.sub.3 is a C1-C3 alkyl group, or O, R is C1-C4 alkyl group, R.sub.1 and R.sub.2 are independently a C1-C3 alkyl group, a is 0 or 1, b is an integer of 0-3, and * represents a bond with U; Y is a hydrogen atom or a halogen atom; and m is an integer of 3 to 5.

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

Chromophores with large hyperpolarizabilities, films with electro-optic activity comprising the chromophores, and electro-optic devices comprising the chromophores are disclosed.

Provided is a method for producing a deuterated aromatic compound and a deuterated reaction composition. The method includes performing a deuterated reaction of an aromatic compound including one or more hydrocarbon aromatic rings using a solution comprising heavy water, an organic compound which can be hydrolyzed by the heavy water, the aromatic compound, and an organic solvent. The method has an advantage in that impurities due to hydrogen gas are not generated, the deuterium substitution rate is high, and the deuterated reaction can be performed under a lower pressure and a lower temperature.

Provided in the present disclosure is an organic compound, which relates to the technical field of organic materials. In the compound of the present disclosure, an electron-deficient nitrogen-containing heteroaryl and cyano are linked to adamantly, so that the LUMO energy level is deepened, thereby electron mobility is further improved. Further provided in the present disclosure are an electronic component and electronic apparatus comprising the described organic compound. The organic compound can improve the electron transport performance of electronic components. When used as an electron transport layer of an organic light-emitting electroluminescent device, the compound can improve the luminous efficiency and service life of the device and reduce the working voltage.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor or M.sub.1 and M.sub.4 receptors and which are useful in the treatment of muscarinic M.sub.1 or M.sub.1/M.sub.4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula

##STR00001##

wherein Q.sup.4, Q.sup.5, R.sup.5, p, V, Q.sup.1, Q.sup.2, X.sup.1, X.sup.2 and W are defined herein.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor or M.sub.1 and M.sub.4 receptors and which are useful in the treatment of muscarinic M.sub.1 or M.sub.1/M.sub.4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula

##STR00001##

wherein Q.sup.4, Q.sup.5, R.sup.5, p, V, Q.sup.1, Q.sup.2, X.sup.1, X.sup.2 and W are defined herein.

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.